Mots-clés
Organismes > OEDT
OEDTSynonyme(s)Observatoire européen des drogues et des toxicomanies European Monitoring Centre for Drugs and Drug Addiction |
Documents disponibles dans cette catégorie (454)
Rapport
This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU. This includes describing the 'pre-precursor' phenomenon and r[...]Rapport
This Thematic paper contains the results of a study that examined drug prevention interventions for minority ethnic populations in 29 European countries. A total of 33 interventions were reported to the study and the issues they raise are presen[...]Rapport
This publication provides an update on drug-related deaths in Europe, presenting and analysing the latest data and trends in drug-induced deaths and overall mortality among high-risk drug users in the European Union and beyond. It draws on contr[...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; F. MATHIS ; D. HEDRICH ; J. VICENTE ; A. NOOR | Lisbon : OEDT / EMCDDA | Technical reports | 2021This report provides an update on drug-related deaths in Europe based primarily on presentations and discussions held at the 2019 meeting of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) expert network on drug-related deat[...]Rapport
On 30 September and 1 October 2021, the EMCDDA brought together more than 60 European and international experts for the annual meeting on the key indicator Drug-related deaths. The online meeting provided a space for sharing and discussing new d[...]Document texte divers
EMCDDA Conference on 20 years of monitoring and communicating evidence on drugs (21-22 September 2015; Lisbon) ; I. GIRAUDON ; J. MATIAS ; L. MONTANARI ; D. HEDRICH ; R. SIMON ; J. VICENTE | Lisbon : OEDT / EMCDDA | 2015Drug use, in particular high-risk drug use, is one of the major causes of avoidable mortality among young people in Europe, both directly through overdose and indirectly through drug-related diseases, accidents, violence and suicide. The Drug-r[...]Rapport
This report is part of the EMCDDA activity around the development and improvement of drug supply indicators, which are designed to reflect developments in drug markets as well as the markets' wider harms and impact. The protocol in this document[...]Rapport
Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a [...]Rapport
This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while high[...]Rapport
This report presents an overview of infectious diseases among people who inject drugs in Europe, both in the community and in prison settings, covering disease surveillance, outbreak investigations, and prevention and control, for the period up [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe for the period up to June 2015. The report covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and[...]Document texte divers
EMCDDA Conference on 20 years of monitoring and communicating evidence on drugs (21-22 September 2015; Lisbon) ; I. GIRAUDON ; L. WIESSING ; E. KALAMARA ; D. HEDRICH ; R. SIMON ; K. PALCZAK ; J. VICENTE | Lisbon : OEDT / EMCDDA | 2015Drug-related infectious diseases (DRID) are among the most serious health consequences of drug use. The DRID indicator collects data on the extent of drug-related infections among people who inject drugs. This group is a key population affected [...]Chapitre
This Selected issue is not intended to present a systematic and exhaustive review either of all possible definitions of drug-related public nuisance or of all measures, provisions and policies aimed at reducing the problem in the European Union,[...]Rapport
An update on the EMCDDA 2008 Selected Issue on drug-related research, this thematic paper identifies current and future challenges and opportunities for drug-related research in Europe.Rapport
OEDT = EMCDDA ; L. LANIEL ; R. KASECKER ; T. GROSHKOVA ; C. CARPENTIER | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013Drug law enforcement activity targets the supply of drugs and is responsible for much of the key data that informs our understanding of drugs supply in Europe. This study looks, for the first time, at how drug law enforcement is organised in Eur[...]Article : Périodique
Interventions to tackle the supply of drugs are seen as standard components of illicit drug policies. Therefore drug market-related administrative data, such as seizures, price, purity and drug-related offending, are used in most countries for p[...]NouveautéRapport
OEDT = EMCDDA ; E. QUIGLEY ; R. SEDEFOV ; C. CARPENTIER ; L. LANIEL ; European Commission, COWI Consortium for DG Health and Consumers | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013The production and trafficking of illicit drugs poses complex and interlinked problems, which have a negative impact on public health and the security and stability of society. Focusing on actions directed at the EU's internal security situation[...]Rapport
This report presents a summary of the key findings from drug treatment facility surveys carried out in 2017 in Albania, Bosnia and Herzegovina, Serbia and the territory of Kosovo. The results provide insight into the characteristics and capacity[...]Chapitre
R. HARTNOLL ; 46th semiannual meeting of the CEWG (June 8-11, 1999; Vancouver, BC, Canada) | Bethesda, MD : NIDA | 1999FRANÇAIS : L'EMCDDA (European Monitoring Centre for Drugs and Drug Addiction : Observatoire Européen des Drogues et des Toxicomanie) a été fondé en vue de fournir des informations relatives aux tendances et types de consommation de drogues dan[...]Rapport
The result of the EMCDDA's cooperation with countries in the Western Balkans over many years, this report is the first of its kind. It gives insight into the drug-related problems faced by six countries in the region, through the available data [...]Rapport
FRANÇAIS : Il semble que la consommation précoce de substances psychoactives, comme l'alcool et le tabac, soit associée avec un risque accru de développer des problèmes liés à la drogue par la suite. Dans cette « Question spécifique », publiée[...]Rapport
A. G. VERSTRAETE ; S. A. LEGRAND ; L. VANDAM ; B. HUGHES ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2014FRANÇAIS : Cette revue de la bibliographie nous propose un rapport détaillé sur la relation entre l'usage de drogues, la réduction des capacités de conduite et les accidents de la route. Le rapport examine des questions méthodologiques, présen[...]Chapitre
The comparative analysis of drug consumption continues in later sections, specifically Zobel and Götz examining regional commonalities and national divergences in European drug use trends. They argue that while illicit drug use varies widely bet[...]Rapport
OEDT = EMCDDA ; L. ROYUELA ; L. MONTANARI ; M. ROSA ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2014The report presents a review of tools for monitoring illicit drug use in prison population in Europe. The objective of the report is to describe the existing tools used at national level, to assess their comparability and to build a common Europ[...]Rapport
This report is based on work commissioned by the EMCDDA in 2009. It examines differences in methods and results between general population surveys conducted in a single context (focusing exclusively on substance use) and a multi context (focusin[...]Rapport
FRANÇAIS : Depuis la fin des années 1990, de nombreuses études européennes et mondiales ont abordé la problématique de la conduite sous l'influence de substances psychoactives. Dans cette « Question spécifique », publiée en marge de son Rappor[...]Rapport
FRANÇAIS : La politique sociale en Europe a depuis longtemps identifié les populations défavorisées qui courent un risque d'exclusion sociale. Ces «groupes vulnérables» désignent des groupes spécifiques au sein de la population, qui sont plus [...]Congrès
Commission européenne = European Commission, Organisateur de réunion ; P. KENIS ; Drugs: Research related initiatives in the European Union (13 and 14 December 1996; The Robert Schuman centre, European University Institute, Florence) | Lisbon : OEDT / EMCDDA | Joint publications | 1997In 1996, representatives of the 15 Member States and individual researchers were invited to a joint seminar, organised by the European Commission and the EMCDDA, entitled 'Drug research-related initiatives in the European Union'. The seminar was[...]Rapport
This paper presents a definition of e-health and m-heath tools to address substance use problems, and a taxonomy to describe such tools systematically. A number of examples of e-health tools that are currently being used in Europe for prevention[...]Rapport
OEDT = EMCDDA ; A. GALLEGOS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2012This publication presents 30 profiles of the national early warning systems on new psychoactive substances in operation in Europe in 2011. The early warning system on new psychoactive substances is a multidisciplinary network consisting of 30 Eu[...]Article : Périodique
A. GOOSDEEL ; P. GRIFFITHS ; H. BERGERON ; M. NILSON ; D. HEDRICH ; R. SEDEFOV |FRANÇAIS : Cet exposé fait le point sur les informations disponibles sur la situation en matière de drogues dans l'Union élargie et propose des références sources pour ceux qui veulent approfondir la question. Les conclusions qui suivent résum[...]Congrès
The conference "Identifying Europes information needs for effective drug policy" marked the 15th anniversary of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and our activity of monitoring drugs and drug addiction in the [...]Rapport
A. ORIGER | Luxembourg [Luxembourg] : Ministrère de la Santé. Service d'action socio-thérapeutique ; Point focal OEDT | 1996In the framework of the EMCDDA Epidemiology work programme 1996, the Luxembourgish Focal Point has been charged to perform a comparative study on national encoding systems and Procedures to Avoid Double Counting in Drug Treatment Reporting Syste[...]Rapport
FRANÇAIS : Les nouvelles drogues officiellement signalées à l'OEDT et à Europol en 2009 via le système d'alerte précoce de l'UE sur les nouvelles substances psychoactives (Early-warning system/EWS) ont atteint un chiffre record. C'est ce qui se[...]Rapport
FRANÇAIS : De nouvelles substances psychoactives deviennent largement disponibles à un « rythme sans précédent ». En 2010, un nombre record de nouvelles drogues ont été officiellement signalées à l'OEDT et à Europol par le biais du système d'al[...]Rapport
FRANÇAIS : De nouvelles drogues ont été détectées dans l'Union européenne l'année dernière, à raison d'une par semaine environ, selon le rapport annuel conjoint de l'OEDT et d'Europol (2011) sur les nouvelles substances psychoactives publié auj[...]Rapport
FRANÇAIS : Le rapport annuel 2013 OEDT-Europol, qui fait le point sur les nouvelles drogues, indique que le nombre, le type et la disponibilité des nouvelles drogues en Europe ont continué à croître en 2012. Elles étaient au nombre de 49 en 201[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2013, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and c[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2014, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and c[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, i[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two or[...]Rapport
In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been [...]Rapport
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as alpha-pyrrolidinovalerophenone (alpha-PVP), through a joint assessment. The two org[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment. The two organisat[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation '25I-NBOMe', submitted in December 2013 to the Council of the EU, the European Commission an[...]Rapport
In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4′-DMAR). The two organisations concluded th[...]Rapport
At the end of 2011 and in 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methylamphetamine. The two organisations concluded that sufficient information had been accumulated to merit the product[...]Rapport
At the end of September 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation '5-IT'), through a joint assessment. The two organisations conclu[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint asses[...]Rapport
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment.[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint asses[...]Rapport
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint ass[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organis[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a [...]Article : Périodique
B. PULVER ; S. FISCHMANN ; A. GALLEGOS ; R. CHRISTIE |Synthetic cannabinoids (SCs), often sold as "legal" replacements for cannabis, are the largest group of new psychoactive substances monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Currently, close to 240 struct[...]Rapport
Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and sub[...]Rapport
Rapport
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]Rapport
This paper is part of the EMCDDA activity around the development and improvement of drug supply indicators, with a focus on drug-related homicide. It builds upon the 2017 review of the academic research and data sources on drug-related homicide [...]Rapport
G. HAY ; N. McKEGANEY ; E. BIRKS ; L. WIESSING ; R. HARTNOLL ; P. Y. BELLO ; C. M. COMISKEY ; D. D'IPPOLITI ; A. DOMINGO-SALVANY ; FREIRE S. ; M. MOREIRA ; NORÉN A. ; PARTANEN P. ; POLITIKOU K. ; SEIDLER D. ; F. SMIT ; TOET J. ; A. UHL ; VIRTANEN A. | Lisbon : EMDCCA | 1997ENGLISH : This report presents the findings from an EMCDDA funded Methodological Pilot Study of Local Level Prevalence Estimates. Following on from a joint EMCDDA / Pompidou Group meeting, comparative pilot studies to improve the prevalence es[...]Rapport
Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control mea[...]Rapport
FRANÇAIS : Depuis le début de l'année 2020, le monde connaît une situation sanitaire sans précédent causée par la pandémie de coronavirus (COVID-19), qui a conduit à l'introduction progressive de mesures de distanciation sociale et d'autres mes[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug ser[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people w[...]Rapport
Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an emergency department ma[...]Rapport
Ce rapport tente de combler une partie du manque de connaissance sur le trafic, la consommation des drogues illicites et des médicaments psychotropes en Afrique. Il dresse un inventaire des organismes spécialisés intervenants dans le champ spéci[...]Rapport
FRANÇAIS : Le Rapport ESPAD 2015 présente les expériences et les perceptions des élèves concernant diverses substances, comme le tabac, l'alcool, les drogues illicites, les produit à inhaler, les médicaments et les nouvelles substances psychoa[...]Rapport
FRANÇAIS : L'usage de tabac et d'alcool chez les élèves de 15 à 16 ans donne des signes de déclin, mais la consommation potentiellement problématique de cannabis et les difficultés posées par les nouvelles conduites addictives soulèvent des in[...]Rapport
This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European level was made.Rapport
This report presents estimates of aggregate market size for the different drugs at EU and European level and describes in detail how these estimates were achieved. Country level estimates are not reported given the uncertainty around some of the[...]Rapport
This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA.Rapport
OEDT = EMCDDA ; A. SARASA-RENEDO ; G. BARRIO ; L. MONTANARI ; B. GUARITA ; L. DE LA FUENTE ; M. J. BRAVO ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2015FRANÇAIS : Ce rapport décrit les tendances en matière d'injection de drogues dans les États membres de l'UE, la Norvège et la Turquie entre 2000 et 2011, à travers une analyse des données relatives aux personnes recevant un traitement médicamen[...]Rapport
L'étude a révélé que l'information non-gouvernementale relative à la problématique évoquée était fortement sous-exploitée, principalement par manque de ressources techniques et d'appuis méthodologiques adaptés. Trois principes fondamentaux ont é[...]Document multimédia
"EU Drug Market: Amphetamine" describes the European amphetamine market from production and trafficking, to distribution and use. It details the processes, materials and actors involved at different stages and levels of the market. Taking a thre[...]Rapport
This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerg[...]Document multimédia
'EU Drug Market: Cannabis' describes the European cannabis market from production and trafficking, to distribution and use. It details the processes, materials and players involved at different stages and levels of the market. The module takes a[...]Rapport
Document multimédia
What are the latest changes in the EU opioids market? How are global geopolitical developments impacting supply? Are heroin trafficking routes changing? To what extent do synthetic opioids pose a threat to Europe? These are among the issues expl[...]Rapport
Rapport
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other cr[...]Rapport
FRANÇAIS : Le présent rapport analyse le phénomène du marché des drogues illicites dans le contexte plus large des nouvelles tendances en matière de consommation de drogue, des facteurs culturels et sociaux et des liens avec la criminalité. Les[...]Congrès
Euro-Ibero American seminar : cooperation on drugs and drug addiction policies. Conference proceedings (8-9 October 1998; Oporto) | Luxembourg : Office for Official Publications of the European Communities | 1999FRANÇAIS : Ce séminaire a eu lieu les 8 et 9 octobre 1998 au Portugal dans la perspective de la tenue imminente de 2 sommets réunissant les chefs des gouvernements d'Europe, d'Amérique Latine et des Caraïbes, sur les questions de coopération e[...]Chapitre
Nearly all European countries now frame their drug policy initiatives within an overall national drugs strategy or action plan. An in-depth analysis of drug policy in Europe in this Selected issue reveals a broadening of the scope of these drug [...]Livre
The drug control regime established by the international community has not succeeded in curbing either the demand for, or the offer of, narcotics. But, despite a series of developments in the Americas - including the legalisation of cannabis in [...]Rapport
The aim of this 'quick guide' is to make practical information on prevention quality standards available outside the European Union. A condensed version of EMCDDA Manual 7, it includes a description of the eight stages involved in the drug preve[...]Document multimédia
FRANÇAIS : La diversification de l'offre et de l'usage de drogues crée de nouvelles problématiques pour la politique en matière de drogue, de soins et de santé en Europe. [...] Ce rapport fournit la dernière vue d'ensemble existante de la situa[...]Rapport
In the last year, there has been decriminalisation of all drug use in Portugal, a Policy Note in Belgium to decriminalise cannabis possession, and the start of the process to downgrade the offence of cannabis possession in the UK. This brief rep[...]Rapport
This study aims to give a descriptive overview of the various legal mechanisms used to sanction this phenomenon - whether provisions exist in drug control laws or road traffic laws, the substances addressed, the status and levels of penalties, a[...]Rapport
When a new psychoactive substance appears on the market, legislators need to choose whether to bring it under control of the drug laws, and for public health reasons they may need to do so quickly. A comparative study of the systems and procedur[...]Rapport
This analysis describes and compares the different substances often referred to as "medicinal cannabis" and their methods of administration, as well as the various methods and levels of permission and control under international, EU and national[...]Rapport
This paper analyses primary studies that examine the consequences of drug law changes, and describes their approach and methodologies. They were categorised as changes to laws addressing illegal use and possession, changes in laws regulating leg[...]